ClayTrader : * * $CATB * * Link to Video- watch an...

ClayTrader · 2021-01-29T21:18:47.4130000Z

* * $CATB * * Link to Video- claytrader.com/stock_chart/CATB/?utm_source=social&utm_medium=ihub&utm_campaign=chart watch analysis by clicking HERE

Play Episode

6min

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

Nextech3D.ai reports 257% revenue surge for ARway following strategic Map D acquisition

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to share a significant financial update, highlighting impressive growth for the company’s AR-focused subsidiary, ARway. For the seven-month period ending March 31, 2025, the company reported unaudited revenue of $450,000—marking a remarkable 257% increase compared to the previous audited fiscal year revenue of $126,000, which ended on August 31, 2024. Additionally, the company achieved a strong gross margin of 95%, up from 90% in the prior fiscal year. This sharp increase in revenue and improved profitability reflect the successful integration of Map D's technology and services into ARway’s operations. Gappelberg emphasized that this strategic acquisition has significantly enhanced ARway’s technological capabilities, expanded its product portfolio, and widened its addressable market. The synergies between the two entities have accelerated ARway’s position as a leader in the rapidly growing 3D spatial mapping, augmented reality (AR) navigation, and spatial computing sectors. "The exceptional growth we've seen is a direct result of our strategic focus and the value we’ve unlocked through the acquisition of Map D," said Gappelberg. "By aligning innovative technologies and expanding our market reach, ARway is now better positioned than ever to lead in the next frontier of AI-powered spatial computing." Looking ahead, Nextech3D.ai believes it is strategically poised for continued expansion, supported by strong market demand for advanced 3D modeling, AI, and augmented reality solutions. The company remains committed to leveraging innovation and strategic partnerships to deliver shareholder value and technological excellence. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors

Proactive - Interviews for investors

hVIVO CEO on record FY24 revenue & EBITDA as expansion strategy pays off

hVIVO PLC chief executive Yamin ‘Mo’ Khan takes Proactive's Stephen Gunnion through the company’s record-breaking financial performance in 2024, operational milestones and strategic outlook. hVIVO reported a 12% rise in revenue to just under £63 million, with an EBITDA margin of 26%. Khan highlighted this as a record margin for the company. He noted that, even excluding a one-off facility fee, the margin remained strong at 23%. The company also ended the year with £44 million in cash. Khan explained: “This is all been based on a record number of inoculations… we ran nine challenge trials and our largest field study to date.” He emphasised the company’s transformation, with a move to a purpose-built 50-bed human challenge facility in Canary Wharf, improvements in operational efficiency, and a major expansion of lab and outpatient capacity. Looking ahead, hVIVO is targeting £73 million in revenue for 2025, of which £70 million is already contracted. The company is also launching new challenge models, including Omicron and hMPV, and pursuing its first phase 3 human trial. Khan also discussed recent acquisitions—CRS in Germany and Cryostore in the UK—and confirmed continued dividend payments, with 0.2p per share set for June. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future updates. #hVIVO #ClinicalTrials #HumanChallengeTrials #BiotechNews #EBITDA #RevenueGrowth #Biopharma #DrugDevelopment #CRSAcquisition #CryoStore #VaccineTrials #AntiviralResearch #LifeSciences #PharmaPipeline

Proactive - Interviews for investors

FDA approval sees Orthocell’s Remplir enter multi-billion dollar US nerve market

Orthocell Ltd chairman John van der Wielen talked with Proactive about the company receiving FDA clearance for its nerve repair product, Remplir, paving the way for entry into the multi-billion US healthcare market. The approval marks a significant milestone in Orthocell’s international growth strategy and reflects the strength of its regulatory and clinical capabilities. Van der Wielen emphasised the significance of breaking into the US market in a challenging regulatory environment. “Not many people would have thought with the current US turmoil, a company like ours could achieve FDA clearance,” he said. Orthocell has established operations in the US with logistics and distribution already in place. The company is implementing a hybrid sales model using in-house personnel and regional distributors, aiming for rapid initial uptake with an eye on more exclusive arrangements in the future. Remplir’s three-year shelf life and no temperature control requirement make it ideal for streamlined deployment. He also highlighted that Orthocell has already performed over 2,000 procedures in Australia and anticipates the US market to be 20 to 30 times larger, creating a strong revenue opportunity. With $32 million in cash reserves, the company expects to become cash flow positive within two years. 👉 For more interviews and updates, head to Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications. #Orthocell #FDAApproval #Remplir #NerveRepair #MedicalDevices #BiotechNews #USHealthcare #OrthocellRemplir #InvestorUpdate #ProactiveInvestors #SurgicalInnovation #ASX

Followers	9857
Posts	260342
Boards Moderated	4
Alias Born	12/27/2006

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Go Ad-Free